ArticleHematology. American Society of Hematology. Education Program2020
Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?
Article in Hematology. American Society of Hematology. Education Program, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Recurrent thrombosis and major bleeding in children treated for VTE.Blood advances · 2025Article
- Association Between Antidepressant Use and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Reduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials.Research and practice in thrombosis and haemostasis · 2025Article
- Risk of First Venous Thrombosis by Comparing Different Thrombin Generation Assay Conditions: Results from the MEGA Case-control Study.TH open : companion journal to thrombosis and haemostasis · 2025Article
- Efficacy and Safety of Direct Oral Anticoagulants After Mechanical Thrombectomy in Venous Thromboembolism: A Comparative Study of 55 Patients.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Research progress of NF-κB signaling pathway and thrombosis.Frontiers in immunology · 2023Review
- Predicting Thromboembolism in Hospitalized Patients with Ventricular Thrombus.Reviews in cardiovascular medicine · 2022Article
- Cancer-related stroke: Exploring personalized therapy strategies.Brain and behavior · 2022Review
- ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly.ERJ open research · 2022Review
- Incidence and Predictors of Recurrence and Mortality Following First Venous Thromboembolism Among the Saudi Population: Single-Center Cohort Study.International journal of general medicine · 2022Article
- Effect of Oral Tranexamic Acid on the Blood Transfusion Rate and the Incidence of Deep Vein Thromboembolism in Patients after TKA.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Pulmonary embolism after discharge for COVID-19: A report of two cases.JRSM cardiovascular diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent venous thromboembolism (VTE, or deep vein thrombosis and pulmonary embolism) is associated with mortality and long-term morbidity. The circumstances in which an index VTE event occurred are crucial when personalized VTE recurrence risk is assessed. Patients who experience a VTE event in the setting of a transient major risk factor (such as surgery associated with general anesthesia for >30 minutes) are predicted to have a low VTE recurrence risk following discontinuation of anticoagulation, and limited-duration anticoagulation is generally recommended. In contrast, those patients whose VTE event occurred in the absence of risk factors or who have persistent risk factors have a higher VTE recurrence risk. Here, we review the literature surrounding VTE recurrence risk in a range of clinical conditions. We describe gender-specific risks, including VTE recurrence risk following hormone- and pregnancy-associated VTE events. Finally, we discuss how the competing impacts of VTE recurrence and bleeding have shaped international guideline recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.